Cargando…
Advances in the management of erythropoietic protoporphyria – role of afamelanotide
Erythropoietic protoporphyria (EPP) and the phenotypically similar disease X-linked protoporphyria (XLPP) are inherited cutaneous porphyrias characterized clinically by acute non-blistering photosensitivity, intolerance to sunlight, and significantly reduced quality of life. They are due to marked o...
Autores principales: | Lane, Ashley M, McKay, Jerome T, Bonkovsky, Herbert L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161401/ https://www.ncbi.nlm.nih.gov/pubmed/28003770 http://dx.doi.org/10.2147/TACG.S122030 |
Ejemplares similares
-
Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria
por: Minder, Anna-Elisabeth, et al.
Publicado: (2023) -
Beyond pigmentation: signs of liver protection during afamelanotide
treatment in Swiss patients with erythropoietic protoporphyria, an observational
study
por: Minder, Anna-Elisabeth, et al.
Publicado: (2021) -
Erythropoietic protoporphyria
por: Lecha, Mario, et al.
Publicado: (2009) -
A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria
por: Balwani, Manisha, et al.
Publicado: (2022) -
Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2020)